Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022
24 Mayo 2022 - 12:00PM
Oxurion Announces Upcoming Preclinical Presentation on THR-149 at
KININ2022
Leuven, BELGIUM,
Boston, MA, US – MAY
24,
2022 –
Oxurion NV (Euronext
Brussels: OXUR), a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, with clinical stage assets in vascular
retinal disorders, today announced that an abstract evaluating the
pharmacokinetic properties of THR-149 will be presented at
KININ2022 to be held June 6-8, 2022 in Annecy, France.
THR-149 is a potent plasma kallikrein inhibitor
being developed as a potential new standard of care for the up to
50% of diabetic macular edema (DME) patients showing suboptimal
response to anti-VEGF therapy. Oxurion is studying THR-149 in Part
B of its two-part Phase 2 KALAHARI trial evaluating THR-149 for the
treatment of DME.Details of the presentation:
TITLE: Pharmacokinetics of
THR-149, a potent and specific plasma kallikrein bicyclic peptide
inhibitor
PRESENTER: Marc Vanhove, Head,
Biochemistry & in vitro Pharmacology, Oxurion NV
PRESENTATION DATE AND TIME:
Tuesday, June 7, 2022, 2.30 p.m. CET
About
OxurionOxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to 50% of DME patients showing suboptimal response
to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium,
with corporate operations in Boston, MA. More information is
available at www.oxurion.com.
For more information, please
contact:
|
Oxurion NVTom GraneyChief Executive OfficerTel:
+32 16 75 13 10tom.graney@oxurion.com Michaël DillenChief
Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com |
USConway Communications Beth
Kurth bkurth@conwaycommsir.com Westwicke, an ICR
CompanyChristopher BrinzeyTel: +1 617 835
9304chris.brinzey@westwicke.com |
- OXUR KININ Curtain Raiser 2022.0524
Oxurion Nv (LSE:0G99)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Oxurion Nv (LSE:0G99)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
